Dementia
AI-116
Dementia
Program
Program snapshot
Indication: Dementia (including Alzheimer’s disease)
Stage: Preclinical
IP: PCT filed (PCT/AU2024/050791)
Program Partner: La Trobe University
About AI-116
AI-116 is a fixed-dose combination drug candidate comprising cannabidiol (CBD) and donepezil, an established treatment for dementia. It was identified and prioritised by AlgoraeOS, then independently validated at the Peter MacCallum Cancer Centre.
In preclinical validation, AI-116 demonstrated 53% cell viability compared to 17% with donepezil alone — a compelling early efficacy signal underpinning the PCT patent filing and the ongoing development program.
The current focus is completing pre-clinical experimental techniques to assess AI-116’s performance across established dementia research models. Next steps are clinical trials, subject to pre-clinical success and regulatory approvals.
The Dementia Opportunity
Dementia is a broad decline in cognitive function with no currently available cures. The most common cause is Alzheimer’s disease, which represents approximately 70% of all dementia cases. Over 55 million people worldwide are living with dementia.
The global dementia drugs market is substantial and growing, with urgent unmet need for advancements in early detection and more effective treatments.
Key Data
Fixed-dose combination: cannabidiol (CBD) + donepezil (off-patent pharmaceutical ingredient)
Preclinical validation: 53% cell viability with AI-116 vs 17% with donepezil alone
PCT patent filed: PCT/AU2024/050791
Independent wet-lab validation at Peter MacCallum Cancer Centre
Program partner: La Trobe University / Monash Victorian Heart Institute
Identified by AlgoraeOS from 500,000+ CBD-drug-cell line predictions
Program Lead
Prof. Garrie Arumugam
Dementia Program Lead — La Trobe University
Professor Garrie Arumugam is a Professor of Physiology at La Trobe University. He holds a PhD in Pharmacology from the University of Queensland and completed post-doctoral training at Louisiana State University Health Sciences Center and the National Institute of Health, Baltimore. His research focuses on neuronal cell death mechanisms in stroke and vascular dementia. He has published over 185 articles in high-impact journals including Nature Medicine, Circulation, PNAS, and Nature Communications, with more than 20,000 career citations.
Other Programs
AI-168
Cardiovascular
Stage: Preclinical | PCT Filed
Fixed-dose combination cannabinoid candidate for cardiovascular disease. Preclinical data: 94% endothelial restoration, 80% smooth muscle normalisation.
NTCELL
Parkinson’s
Stage: Phase 2 data under review
Alginate-coated capsule containing neonatal porcine choroid plexus cells. Phase 2 clinical trial data under scientific review. Predates the current dual-track strategy.
Sign Up for Email Updates
"*" indicates required fields